The first trial was a phase 1 dose-escalation trial of affinity-enhanced MAGE-A10 TCR-T cells in patients with MAGE-A10-expressing advanced NSCLC [129]. The gene discussed is MAGEA10; the disease is non-small cell lung carcinoma.